Basic information
Biomarker: AMF
Histology type: endometrial carcinoma
Cohort characteristics
Country: China
Region: Shanghai
Followed up time :
Subgroup 1 name : malignant tissue specimens of the endometrium
Subgroup 1 number: 31
Subgroup 2 name: normal
Subgroup 2 number: 31
Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
---|---|---|---|---|---|---|---|---|
62 | malignant tissue specimens of the endometrium | 31 | normal | 31 |
Sample information
Conclusion: AMF may provide a potential prognostic and therapeutic target in preventing EC progression.
Sample type : tissue
Sample method: Immunohistochemistry
Expression pattern : positive expression
Expression elevation: The staining intensity was scored as 0 (negative),1 (weak), 2 (medium) or 3 (strong). The extent of staining was scored as 0 (0%), 1 (1-25%), 2 (26-50%), 3 (51-75%) or 4 (76-100%), according to the percentage of the positively stained areas in relation to the whole tumor area. The sum of the intensity score and the extent score was used as the final staining score (0-7). Tumors with a final staining score of 4 or higher were considered ‘positive’
Disease information
Related information
Funtion description: Gene expression profile revealed that AMF silencing resulted in altered expression of EMT related molecular mediators including Snail and transforming growth factor β receptor 1, and involvement of mitogen-activated protein kinase (MAPK) signaling pathway.EMT related markers were downregulated with pretreatment of the MAPK-specific inhibitor U0126 by western blotting.
Funtion Uniprot: In the cytoplasm, catalyzes the conversion of glucose-6-phosphate to fructose-6-phosphate, the second step in glycolysis, and the reverse reaction during gluconeogenesis (PubMed:28803808). Besides it's role as a glycolytic enzyme, also acts as a secreted cytokine: acts as an angiogenic factor (AMF) that stimulates endothelial cell motility (PubMed:11437381). Acts as a neurotrophic factor, neuroleukin, for spinal and sensory neurons (PubMed:3352745, PubMed:11004567). It is secreted by lectin-stimulated T-cells and induces immunoglobulin secretion (PubMed:3352745, PubMed:11004567).
UniProt ID: P06744
UniProt Link: https://www.uniprot.org/uniprotkb/P06744/entry
Biological function from UniProt: #Gluconeogenesis #Glycolysis
Molecular function from UniProt:
Subcellular UniProt: #Cytoplasm #Secreted
Alternative name from UniProt:
Catalytic activity: alpha-D-glucose 6-phosphate = beta-D-fructose 6-phosphate
Activity regulation: Strongly inhibited by erythrose 4-phosphate.
Recommended name: Glucose-6-phosphate isomerase
Gene name from HGNC: GPI (AMF, NLK)
HPA class: Cancer-related genes Disease related genes Enzymes Human disease related genes Metabolic proteins Plasma proteins Potential drug targets
AlphaFold DB: P06744
AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P06744
HPA link: https://www.proteinatlas.org/ENSG00000105220-GPI
Tissue specificity RNA from HPA: Low tissue specificity
Tissue expression from HPA: Cytoplasmic expression at variable levels in most tissues.
Single cell type specificity Cell type enhanced (Late spermatids, Early spermatids)
Immune cell specificity: Low immune cell specificity
Subcellular summary HPA Located in Nucleoplasm, Plasma membrane, Cytosol (Single cell variability)
Cancer prognostic summary HPA Gene product is not prognostic
Pathology link: https://www.proteinatlas.org/ENSG00000105220-GPI/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000105220-GPI/pathology/endometrial+cancer
Phenotype ID: 613470
Disease: Hemolytic anemia, non-spherocytic, due to glucose phosphate isomerase deficiency (HA-GPID)
Note1: The disease is caused by variants affecting the gene represented in this entry
OMIM: 172400
OMIM link1: https://www.omim.org/entry/613470
OMIM link2: https://www.omim.org/entry/172400
HGNC ID: HGNC:4458
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4458